Premium
Roles of S ema4 A in multiple sclerosis and interferon‐β therapy efficacy
Author(s) -
Nakatsuji Yuji,
Okuno Tatsusada,
Koda Toru,
Takata Kazushiro,
Honorat Josephe A.,
Mochizuki Hideki,
Kumanogoh Atsushi
Publication year - 2013
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12070
Subject(s) - multiple sclerosis , medicine , interferon , oncology , combination therapy , immunology
The early initiation of appropriate treatment is important for a better prognosis for patients with multiple sclerosis ( MS ). Although interferon ( IFN ‐β) has been the most prescribed therapy for MS , some patients are poor responders to this therapy. Therefore, finding biomarkers to predict treatment responsiveness is required. Some patients with MS have high serum S ema4 A and concurrently have characteristics of T h17‐skewing conditions, and do not respond well to IFN ‐β therapy. In the present review, we discuss S ema4 A and responsiveness to IFN ‐β therapy. In addition, we review biomarkers relevant to IFN ‐β therapy responsiveness.